
Rein Therapeutics doses first subject in Phase II trial to treat IPF
US-based biopharmaceutical company Rein Therapeutics has dosed the first subject in a Phase II trial of LTI-03, its lead asset for treating idiopathic pulmonary fibrosis (IPF). The double-blind, placebo-controlled RENEW trial is set to assess the …